The influence of established and new antiepileptic drugs on visual perception. 1. A placebo-controlled, double-blind, single-dose study in healthy volunteers

Epilepsy Research

Volumn 29, Issue 1, 1997, Pages 35-47

  Steinhoff, Bernhard J ^a   Freudenthaler, Nóra ^a   Paulus, Walter ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Carbamazepine; Controlled trial; Gabapentin; Lamotrigine; Losigamone; Valproic acid; Vigabatrin; Visual perception

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; LOSIGAMONE; VALPROIC ACID; VIGABATRIN;

ADULT; ANTICONVULSANT ACTIVITY; ARTICLE; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL FLICKER FUSION; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; ION CONDUCTANCE; MALE; NAUSEA; NORMAL HUMAN; NYSTAGMUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPATIAL FREQUENCY DISCRIMINATION; VERTIGO; VISUAL ACUITY; VISUAL ADAPTATION;

ADAPTATION, OCULAR; ADMINISTRATION, ORAL; ADULT; ANTICONVULSANTS; COLOR PERCEPTION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLICKER FUSION; HUMANS; MALE; PSYCHOMETRICS; PSYCHOPHYSICS; REFERENCE VALUES; SENSORY THRESHOLDS; VISUAL PERCEPTION;

EID: 0030729596     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(97)00060-0     Document Type: Article

References (70)

1. Engel J, Jr. Seizures and Epilepsy. Philadelphia, PA: Davis, 1989.
2. Löscher W., Schmidt D. Strategies in antiepileptic drug development: Is rational drug design superior to random screening and structural variation? Epilepsy Res. 17:1994;95-134.
3. MacDonald RL, Meldrum BS. Principles of antiepileptic drug action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic Drugs, 4th edition. New York: Raven Press, 1995:61-77.
4. Traub R.D., Wong R.K. Cellular mechanism of neuronal synchronization in epilepsy. Science. 216:1982;745-747.
5. Lampe H., Bigalke H. Carbamazepine blocks NM DA-activated currents in cultured spinal cord neurons. Neuroreport. 1:1990;8-10.
6. Leach M.J., Marden C.M., Miller A.A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. 27:1986;490-497.
7. Löscher W. Valproinsäure: Pharmakodynamische wirkungen und biochemische wirkungsmechanismen. In: Kramer G, Laub MC, editors. Valproinsaure. Berlin: Springer, 1992:3-23.
8. Taylor CP. Gabapentin. Mechanism of action. In: Levy RH, Mattson RH, Meldrum BS, editors, Antiepileptic Drugs, 4th edition. New York: Raven Press, 1995:829-841.
9. Ziemann U, Lonnecker S, Steinhoff BJ, Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: A transcranial magnetic stimulation study. Ann Neurol 1996;40:367-378.
10. Bayer A. Retinale Funktionsstorungen bei Patienten unter antikonvulsiver Therapie. Medical thesis, University of Tubingen, 1991.
11. Bayer A., Thiel H.-J., Zrenner E., Paulus W., Ried S., Schmidt D. Colour vision deficiencies and enhanced sensitivity to glare in epileptic patients treated with carbamazepine and phenytoin: ocular side effects of antiepileptic drug. Nervenarzt. 66:1995;89-96.
12. Bayer A., Thiel H.-J., Zrenner E., Paulus W., Ried S., Schmidt D. Sensitive physiological tests for ocular side effect of drugs: antiepileptics. Ophthalmologe. 92:1995;192-198.
13. Paulus W., Schwarz G., Steinhoff B.J. The effect of anti-epileptic drugs on visual perception in patients with epilepsy. Brain. 119:1996;539-549.
14. Gotz E., Feuerstein T.J., Lais A., Meyer D.K. Effects of gabapentin on release of gamma-aminobutyric acid from slices of the rat neostriatum. Arzneim-Forsch Drug Res. 43:1993;636-638.
15. Kocsis J.D., Hommou O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci Lett. 169:1994;181-184.
16. Löscher W., Honack D., Taylor C.P. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions in rat brain. Neurosci Lett. 128:1991;150-154.
17. Taylor C.P., Vartanian M.G., Yuen P.-W., Bigge C., Suman-Chauhan N., Hill D.R. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. 14:1992;11-15.
18. Lanthony P. The desaturated panel-D-15. Doc Ophthalmol. 46:1978;185-189.
19. Bowman K.J. A method for quantitative scoring of the Farnsworth panel D-15. Acta Ophthalmol. 60:1982;907-916.
20. Mollon J.D., Polden P.G. Colour illusion and evidence for interaction between cone mechanisms. Nature. 258:1975;421-422.
21. Mollon J.D., Polden P.G. Absence of transient tritanopia after adaptation to very intense yellow light. Nature. 259:1976;570-572.
22. Mollon J.D., Polden P.G. Saturation of a retinal cone mechanism. Nature. 265:1977;243-246.
23. Mollon J.D., Polden P.G. An anomaly in the response of the eye to light of short wavelength. Philos Trans R Soc Lond Ser B. 278:1977;207-240.
24. Mollon J.D., Polden P.G. Post-receptoral adaptation. Vision Res. 19:1979;435-440.
25. Paulus W., Schwarz G., Werner A., Lange H., Bayer A., Hofschuster M., Muller N., Zrenner E. Impairment of retinal increment thresholds in Huntington's disease. Ann Neurol. 34:1993;574-578.
26. Stiles W.S. Increment thresholds and mechanisms of colour vison. Doc Ophthalmol. 3:1949;138-163.
27. Stiles W.S. Investigations of the scotopic and trichromatic mechanisms of vision by the two-colour threshold technique. Rev Opt. 28:1949;215-237.
28. Zrenner E. Neurophysiological Aspects of Color Vison in Primates. Berlin: Springer, 1983.
29. Hermsteiner E-M. Das Farbwahrnehmungsphanomen, 'Transiente Tritanopie' als Indikator fur eine Affektion der retinalen Neurotransmission beim M. Parkinson, unter Neuroleptika-Therapie und bei der Chorea Huntington. Medical thesis, University of Gottingen, 1994.
30. Paulus W.M., Homberg V., Cunningham K., Halliday A.M., Rohde N. Colour and brightness components of foveal visual evoked potentials in man. Electroenceph Clin Neurophysiol. 58:1984;107-119.
31. MacAdam D.L. Uniform color scales. J Opt Soc Am. 64:1974;1691-1702.
32. Aldenkamp A.P., Alpherts W.C.J., Diepmann L., Van't Slot B., Overweg J., Vermeulen J. Cognitive side-effects of phenytoin compared with carbamazepine in patients with localization-related epilepsy. Epilepsy Res. 19:1994;37-43.
33. Tomson T., Nilsson B.Y., Levi R. Impaired visual contrast sensitivity in epileptic patients treated with carbamazepine. Arch Neurol. 45:1988;897-900.
34. Slaughter M.M., Bai S.-H. Baclofen's suppression of epileptiform-like activity: a retinal model. Neurosci Res Suppl. 8:1988;S217-S229.
35. Lippert B., Metcalf B.W., Jung M.J., Casara P. 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotransferase in mammalian brain. Eur J Biochem. 74:1997;441-445.
36. Petroff O.A.C., Rothman D.L., Behar K.L., Collins T.L., Mattson R.H. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology. 47:1996;1567-1571.
37. Vermeulen J., Aldenkamp A.P. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res. 22:1995;65-95.
38. Winer BJ, Brown DR, Michels KM. Statistical Principles in Experimental Design. 3rd edition. New York: McGraw-Hill, 1991.
39. Rothman K.J. No adjustments are needed for multiple comparisons. Epidemiology. 1:1990;43-46.
40. Pokorny J, Smith VC. Assessment of S-cone sensitivity. In: Drum B, editor. Colour vision deficiencies Xll. Dordrecht: Kluwer, 1995:299-308.
41. Cohen E.D., Miller R.F. The role of NMDA and non-NMDA excitatory amino acid receptors in the functional organization of primate retinal ganglion cells. Vis Neurosci. 11:1994;317-332.
42. Copenhagen DR, Mitiman S, Taylor WRM, Dixon DB. Glutamergic synaptic excitation of retinal amacrine and ganglion cells. In: Shapley R, Lam DM, editors. Contrast Sensitivity, Cambridge London: MIT Press, 1993:41-57.
43. Crooks J., Kolb H. Localization of GABA, glycine, glutamate and tyrosine hydroxylase in the human retina. J Comp Neurol. 315:1992;287-302.
44. Davanger S., Ottersen O.P., Storm-Mathisen J. Glutamate, GABA, and glycine in the human retina: an immunocytochemical investigation. J Comp Neurol. 311:1991;483-494.
45. 3H] GABA preferentially from horizontal cells. Brain Res. 398:1986;276-287.
46. Wassle H., Boycott B.B. Functional architecture of the mammalian brain. Physiol Rev. 71:1991;447-480.
47. Wassle H., Boycott B.B., Rohrenbeck J. Horizontal cells in the monkey retina: cone connections and dendritic network. Eur J Neurosci. 1:1989;421-435.
48. Wassle H., Chun M.H. GABA-like immunoreactivity in the cat retina: light microscopy. J Comp Neurol. 279:1989;43-54.
49. Yazulla S., Kleinschmidt J. Dopamine blocks carrier-mediated release of GABA from retinal horizontal cells. Brain Res. 233:1982;211-215.
50. Dowling JE. Information processing by local circuits. The vertebrate retina as a model system. In: Schmitt FO, Worden FG, editors. The Neurosciences, Fourth Study Program, Cambridge, MA: MIT Press, 1979:163-181.
51. 3H] gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur J Pharmacol. 244:1993;293-301.
52. Goldlust A., Su T.-Z., Welty D.F., Taylor C.P., Oxender D.L. Effetcs of anvticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res. 22:1995;1-12.
53. Taylor C.P. Emerging perspectives on the mechanism of action of gabepentin. Neurology. 44(5):1993;S10-S16.
54. Steinhoff BJ, Freudenthaler N, Paulus W. The influence of established and new antiepileptic drugs on visual perception. ll. A controlled study in patient with epilepsy under long-term antiepileptic medication. Epilepsy Res 1997;29:49-58.
55. Loscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res. 501:1989;198-203.
56. 1H] magnetic resonance spectroscopy and valproate [Abstract]. Epilepsia. 36(3):1995;S145-S146.
57. Slaughter MM, Tian N. You cannot inhibit a good receptor: GABA receptor diversity in the vertebrate retina. In: Shapley R, Lam DM, editor. Contrast Sensitivity. Cambridge, London: MIT Press, 1993:59-73.
58. Kaplan E, Lee BB, Shapley RM. New views of primate retinal function. In: Osborne N, Chader J, editors. Progress in Retinal Research, vol. 9. Oxford, New York, Bejing, Frankfurt, Sao Paulo, Sydney, Tokyo, Toronto: Pergamon Press, 1991:273-336.
59. Cucchiaro J.B., Bickford M.E., Sherman S.M. A gabaergic projection system from the pretectum in the dorsal lateral geniculate nucleus in the cat. Neuroscience. 41:1991;213-226.
60. 0tt H, Kranda H. Flicker techniques in Psychopharmacology. Weinheim: Beltz, 1982.
61. McLean M.J., Macdonald R.L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther. 237:1986;1001-1011.
62. Leach M.J., Baxter M.G., Critchley M.A. Neurochemical and behavioral aspects of lamotrigine. Epilepsia. 32(Suppl 2):1991;S4-S8.
63. Leach MJ, Lees G, Riddall DR. Lamotrigine. Mechanism of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic Drugs, 4th edition. New York: Raven Press, 1995:861-869.
64. Kapetanovic L.M., Yonekawa W.D., Kupferberg H.J. The effects of anticonvulsant compounds on 4-aminopyridine-induced de novo synthesis of neurotransmitter amino acids in rat hippocampus in vitro. Epilepsy Res. 20:1995;113-120.
65. Kohr G., Heinemann U. Effects of tetronic acid derivates AO-33 (losigamone) and AO-78 on epileptiform activity and on stimulus induced calcium concentration changes in rat hippocampal slices. Epilepsy Res. 7:1990;49-55.
66. Zhang C.L., Chatterjee S.S., Stein U., Heinemann U. Comparison of the effects of losigamone and its isomers on maximal electroshock induced epileptiform activity in slices of the rat temporal cortex. Naunyn-Schmiedeberg's Arch Pharmacol. 345:1992;85-92.
67. Dimpfel W., Chatterjee S.S., Noldner M., Ticku M.K. Effects of the anticonvulsant losigamone and its isomers on the GABAA receptor system. Epilepsia. 36:1995;983-989.
68. Coulter D.A., Huguenard J.R., Prince D.A. Specific petit mal anticonvulsants reduce calium currents in thalamic neurons. Neurosci Lett. 98:1989;74-78.
69. Macdonald RL, McLean MJ. Anticonvulsant drugs: Mechanisms of action. In: Delgado-Escueta AV, Ward JR, Woodbury DM, Porter RJ, editors. Advances in Neurology. New York: Raven Press, 1986:713-736.
70. Kerwin R.W., Olpe H.R., Schmutz M. The effect of sodium-n-dipropyl acetate on GABA dependent inhibition in rat cortex in vivo. Br J Clin Pharmacol. 71:1980;545-551.